Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim F Greten

Showing results (181-190 of 223) with videos related to

Pageof 23
Sort By:
Cancer Immunology Research|July 1, 2021
Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor ResponseBenjamin Ruf, Vanessa V Catania, Simon Wabitsch, et al.
Cancer Medicine|January 11, 2024
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinomaCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver TransplantationLorenz Kocheise, Gabriel Bacil, Pavan Bhimalli, et al.
Gut|September 28, 2023
Immunosuppressive CD29<sup>+</sup> Treg accumulation in the liver in mice on checkpoint inhibitor therapyBenjamin L Green, Yuta Myojin, Chi Ma, et al.
Journal of Hepatology|July 3, 2021
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinomaLichun Ma, Limin Wang, Subreen A Khatib, et al.
Cancer Letters|August 11, 2025
Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancersChi Ma, Joy A Awosika, Cecilia Monge, et al.
Cell|June 12, 2020
A Viral Exposure Signature Defines Early Onset of Hepatocellular CarcinomaJinping Liu, Wei Tang, Anuradha Budhu, et al.
BMC Cancer|August 29, 2014
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104Steffen Ormanns, Jens T Siveke, Volker Heinemann, et al.
Journal of Hepatology|December 4, 2020
CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinomaLaurence P Diggs, Benjamin Ruf, Chi Ma, et al.
Nature|March 3, 2016
NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesisChi Ma, Aparna H Kesarwala, Tobias Eggert, et al.
Pageof 23

Showing results (181-190 of 223) with videos related to

Sort By:
Pageof 23
Cancer Immunology Research|July 1, 2021
Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor ResponseBenjamin Ruf, Vanessa V Catania, Simon Wabitsch, et al.
Cancer Medicine|January 11, 2024
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinomaCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver TransplantationLorenz Kocheise, Gabriel Bacil, Pavan Bhimalli, et al.
Gut|September 28, 2023
Immunosuppressive CD29<sup>+</sup> Treg accumulation in the liver in mice on checkpoint inhibitor therapyBenjamin L Green, Yuta Myojin, Chi Ma, et al.
Journal of Hepatology|July 3, 2021
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinomaLichun Ma, Limin Wang, Subreen A Khatib, et al.
Cancer Letters|August 11, 2025
Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancersChi Ma, Joy A Awosika, Cecilia Monge, et al.
Cell|June 12, 2020
A Viral Exposure Signature Defines Early Onset of Hepatocellular CarcinomaJinping Liu, Wei Tang, Anuradha Budhu, et al.
BMC Cancer|August 29, 2014
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104Steffen Ormanns, Jens T Siveke, Volker Heinemann, et al.
Journal of Hepatology|December 4, 2020
CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinomaLaurence P Diggs, Benjamin Ruf, Chi Ma, et al.
Nature|March 3, 2016
NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesisChi Ma, Aparna H Kesarwala, Tobias Eggert, et al.
Pageof 23